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We are delighted to inform the readership of Current
Oncology that Dr. Richard J. Ablin, from the Uni-
versity of Arizona College of Medicine and the Ari-
zona Cancer Center, has agreed to join Dr. Phil Gold
as co-deputy editor. We welcome Richard, who has
served on the editorial board of Current Oncology
since 1998 and who is currently co-editor with Phil
Gold of our section on Updates and Developments
in Oncology.
In their respective roles, Phil and Richard will
work together, with the help of our section editors, to
expand the base of submissions from across Canada
and the United States. In this regard, we look to you,
our readership, for input about the kind of material
that you would like to see—and indeed for original
articles for publication in your specific areas of in-
terest and expertise, and for reviews of areas that have
experienced rapid progress on the clinical side.
Furthermore, Phil and Richard, together with
other members of our staff, will be interfacing with
industry and other stakeholders in the oncology com-
munity throughout North America while promoting
Current Oncology and working to further enhance
the impact value of the journal.
We anticipate that these exciting changes will
bring Current Oncology to the next level, thereby fill-
ing a niche for not only for specialists in clinical on-
cology, but also for family physicians who have taken
on major responsibilities in meeting the needs of can-
cer patients. In the process, we trust that Current
Oncology will become an invaluable resource for the
Canadian oncology community.
~
The gene for human epidermal growth factor 2
is amplified in approximately 20% of breast cancers,
and the amplification is the primary mechanism for
HER2 protein overexpression. Overexpression of HER2
is predictive of response to particular therapies, in-
cluding trastuzumab (Herceptin: Genentech, San
Francisco, California, U.S.A.) treatment in the meta-
static and adjuvant settings, and updated Canadian
guidelines for HER2 testing are published in this issue
of the journal. Two additional clinical practice guide-
lines are also included: one on the management of
solitary brain metastasis, and another on the value of
ifosfamide-based combination chemotherapy in ad-
vanced soft-tissue sarcoma. Stephen Sagar, in his role
of section editor of Integrative Therapies, introduces
a manuscript from Edzard Ernst titled “Homeopathy
for cancer?” describing the evolution of the art of
homeopathy over the last 200 years or so. And the
National Cancer Institute of Canada (NCIC) Clinical
Trials Group’s article “Phase II testing of sunitinib:
the National Cancer Institute of Canada Clinical Tri-
als Group IND Program Trials IND.182–185” leads
off a new section of selected Canadian Centre
Activities.
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